Fig. 3From: Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL dataPooled hazard ratios for A hospitalization for heart failure, B all-cause death, C composite of hospitalization for heart failure or all-cause death, D myocardial infarction, and E stroke stratified by subgroups (Intent-to-treat analysis; adjusted). Event rate, events per 100-person years; ACE angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, oGLD other glucose-lowering drug, SGLT-2i sodium–glucose cotransporter-2 inhibitorBack to article page